IVAN ROSAS to Double-Blind Method
This is a "connection" page, showing publications IVAN ROSAS has written about Double-Blind Method.
Connection Strength
0.352
-
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 04 22; 384(16):1503-1516.
Score: 0.124
-
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2018 01; 153(1):94-104.
Score: 0.098
-
A Phase IIb Randomized Clinical Study of an Anti-av?6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 11 01; 206(9):1128-1139.
Score: 0.035
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023 01; 11(1):87-96.
Score: 0.034
-
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 03 01; 50(3):398-409.
Score: 0.033
-
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Adv Ther. 2019 11; 36(11):3279-3287.
Score: 0.028